IDIBELL on the media
New epigenomic strategies in the clinical management of cancer of unknown primary
The invention of the EPICUP® epigenetic test last year allowed physicians to elucidate what type of primary tumor had metastasized in patients with Cancer of Unknown Primary (CUP). Today, an article published in Nature Reviews Clinical Oncology by Dr. Manel Esteller, coordinator of the Epigenetics and Cancer Biology Program of the Bellvitge Biomedical Research Institute […]
A personalized treatment with metabolic therapy improves the motor and communication skills of a patient with atypical Rett syndrome
Administration of the amino acid D-serine, a dietary supplement, contributes to the improvement of the cognitive and motor capacity of a patient with a mutation that affects glutamate receptors A promising treatment with no side effects Towards “express personalization”
A new ribosomal biogenesis regulation point to treat cancer and 5q- syndrome
Researchers in the Oncobell program at the Bellvitge Biomedical Research Institute (IDIBELL) – Catalan Institute of Oncology (ICO) have unveiled a new role for free 40S ribosomes as guardians of genetic information required to synthesize themselves. This mechanism, which relies on a complex of free 40S ribosomes and the RNA binding protein LARP1, is independent […]
Orgull en ciència: L’IDIBELL s’adhereix a la celebració del Dia per l’Alliberament LGTB+
Per a commemorar aquesta diada l’IDIBELL i l’ICO han fet un vídeo per recordar algunes personalitats històriques del món de la ciència i la medicina que han estat pioneres en la lluita per a la igualtat de gènere i la diversitat. . Dia per l’Alliberament LGBTI La diada a Catalunya
Dr. Xavier Matias-Guiu receives an ICS award for his research career
The distinction was granted during the 9th ICS Research Day, which focused on respiratory diseases Xavier Matias-Guiu
Facial paralysis image processing software is awarded a grant by the Academy of Medical Sciences
Researchers from the Rehabilitation and Physiotherapy Department of Bellvitge University Hospital – Bellvitge Biomedical Research Institute (HUB-IDIBELL) have been awarded the VI basic research in physiotherapy grant from the Catalan-Balearic Physiotherapy Society, which will allow them to partially fund the clinical validation of a imaging software prototype designed as a facial neuromuscular therapy in patients […]
The complete epigenomes of the most frequent tumors, unveiled
A research team from the Bellvitge Biomedical Research Institute (IDIBELL) has managed to characterize the complete epigenomes of the most frequent tumors, including those of colon, lung and breast cancer. Their work, published in Oncogene, was led by Dr. Manel Esteller, Director of the Epigenetics and Cancer Biology Program at IDIBELL, ICREA Researcher and Professor […]
IDIBELL leads a new European Innovative Training Network
The four-year project will finance 15 early stage researchers to explain the relationship between cancer, metabolism and the immune system
Scientists identify new predisposing genes and microRNAS involved in hereditary cancer
Dr. Gabriel Capellá presents the hereditary cáncer-related projects of IDIBELL at the XI AECC Symposium
IDIBELL and CMRB launch a new Catalan Regenerative Medicine Program
The Center of Regenerative Medicine in Barcelona (CMR[B]) – currently located within the Barcelona Biomedical Research Park (PRBB) – and the Bellvitge Biomedical Research Institute (IDIBELL) have joined efforts to create the new Regenerative Medicine Program of Catalonia (P-CMR[C]).